ABSTRACT
Symptomatic benign prostatic hyperplasia (BPH) is a common condition in elderly men and has a significant impact on their daily lives. The drugs prescribed for treatment include alpha1-blockers, 5-alpha-reductase inhibitors and plant preparations. Epilobium angustifolium L. is deemed to be helpful in BPH therapy, although there is less information regarding the mechanism of its biological activity. The present study evaluated the effect of E. angustifolium extract on human prostatic epithelial cells (PZ-HPV-7). The exposure to E. angustifolium extract induced a marked inhibition of cell growth in all tested conditions. The anti-proliferative effect observed in in vitro systems clearly indicates a biologically relevant effect of compounds present in the extract. Considering these results, the use in traditional medicine of E. angustifolium extract against BPH seems to be justified. However, further experimental studies are needed to determine the biochemical mechanism of the action and the clinical value of the E. angustifolium extract.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Epithelial Cells/drug effects , Onagraceae/chemistry , Plants, Medicinal/chemistry , Prostate/cytology , Cell Division/drug effects , Cell Line , Cell Survival/drug effects , Humans , L-Lactate Dehydrogenase/metabolism , Male , Plant Extracts/pharmacologyABSTRACT
Macrocyclic lactones 1a-b have been synthesized and their potential therapeutic value evaluated. The key structural feature of these active 'chimera' compounds is the 12-membered lactone ring that brings together the well-known polysubstituted hydroquinone moiety of antioxidants and the alpha,alpha-dimethyl substituted acyl residue of gemfibrozil. Lactones 1a-b showed better activity than probucol, a classical phenolic antioxidant, in preventing the Cu++-induced oxidative modification of human LDL. The hypolipidaemic activity of the new lactones, evaluated as the inhibition of lipids biosynthesis in Hep-G2 cells, was comparable to that of gemfibrozil. These features, added to the lack of cytotoxicity, make this new class of medium sized lactones promising dual-action drugs useful as anti-atherosclerosis agents.
Subject(s)
Antioxidants/pharmacology , Arteriosclerosis/drug therapy , Lactones/pharmacology , Carcinoma, Hepatocellular/metabolism , Cell Line , Cytotoxicity Tests, Immunologic , Electrophoresis, Polyacrylamide Gel , Humans , Hypolipidemic Agents/pharmacology , Magnetic Resonance Spectroscopy , Models, Chemical , Thiobarbituric Acid Reactive Substances , Time FactorsABSTRACT
New 6-chloro-2,3-dihydro-4(1H)-quinazolinones (24-27) have been synthesized and evaluated for gastrointestinal prokinetic and antiemetic activities in comparison with structurally related benzamides (21-22) and 6-chloro-2,3-dihydro-(1H)-1,3-benzoxazolin-4-ones (28). Their key pharmacophoric element has been defined as a 6-membered ring replacing the "virtual ring" arising from the hydrogen bond between amidic nitrogen and methoxy group in metoclopramide (1) and structurally related benzamides (2-10). Variations of heterocycle linking groups have pointed out that a lipophilic aromatic group in position 1 plays an important role for pharmacological properties, while the steric restriction and the modification of the side-chain nucleophilicity are uneffective both for the in vitro and in vivo activity. Some of these compounds very effectively enhance gut peristaltic activity in vitro (rabbit jejunum), increase gastric emptying of a semisolid meal (in rats), and inhibit cisplatin-induced emesis (in pigeons), favourably comparing with cisapride.
